Vectorite Biomedical Inc. (TPEX:4170)
Taiwan · Delayed Price · Currency is TWD 12.70
0.00 (0.00%)
Aug 26, 2026, 1:51 PM CST
Vectorite Biomedical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 54.81 | 61.41 | 57.77 | 55.85 | 42.91 | 28.77 | |
Revenue Growth | -19.28% | 6.29% | 3.43% | 30.15% | 49.16% | 17.22% |
Cost of Revenue | 37.77 | 39.72 | 40.8 | 39.43 | 42.21 | 31.24 |
Gross Profit | 17.04 | 21.68 | 16.97 | 16.42 | 0.71 | -2.47 |
Selling, General & Admin | 26.35 | 28.11 | 25.98 | 25.96 | 25.82 | 26.69 |
Research & Development | 13.87 | 15.48 | 16.96 | 6.59 | 5.43 | 13.25 |
Operating Expenses | 40.22 | 43.59 | 42.94 | 32.56 | 31.24 | 39.95 |
Operating Income | -23.18 | -21.91 | -25.97 | -16.13 | -30.54 | -42.43 |
Interest Expense | -0.01 | -0.01 | - | - | - | - |
Interest & Investment Income | 2.71 | 2.85 | 3.19 | 3.55 | 1.97 | 0.87 |
Earnings From Equity Investments | - | - | - | - | - | -5.84 |
Currency Exchange Gain (Loss) | -0.35 | -0.35 | 0.5 | 0.1 | -0.1 | 0.05 |
Other Non Operating Income (Expenses) | 27.8 | 2.12 | 4.38 | 2.7 | 3.2 | 4.63 |
EBT Excluding Unusual Items | 6.97 | -17.31 | -17.91 | -9.78 | -25.48 | -42.72 |
Gain (Loss) on Sale of Investments | 119.04 | 119.04 | -6.4 | 3.88 | -0.98 | 51.05 |
Gain (Loss) on Sale of Assets | 0.04 | 0.04 | - | - | - | - |
Asset Writedown | -5.63 | -5.63 | -15.77 | -0.73 | - | - |
Pretax Income | 120.42 | 96.14 | -40.07 | -6.63 | -26.45 | 8.33 |
Income Tax Expense | 2.23 | - | - | - | - | - |
Earnings From Continuing Operations | 118.19 | 96.14 | -40.07 | -6.63 | -26.45 | 8.33 |
Minority Interest in Earnings | 0.03 | 0.03 | 0.02 | 0.03 | 0.04 | 0.03 |
Net Income | 118.22 | 96.17 | -40.05 | -6.6 | -26.41 | 8.36 |
Net Income to Common | 118.22 | 96.17 | -40.05 | -6.6 | -26.41 | 8.36 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 | 43 |
Shares Outstanding (Diluted) | 45 | 44 | 44 | 44 | 44 | 43 |
Shares Change | 3.58% | 0.53% | -0.14% | - | 1.84% | 47.01% |
EPS (Basic) | 2.66 | 2.20 | -0.92 | -0.15 | -0.60 | 0.19 |
EPS (Diluted) | 2.65 | 2.19 | -0.92 | -0.15 | -0.60 | 0.19 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -8.76 | -9.78 | -14.35 | -3.46 | 13.81 | -67.59 |
Free Cash Flow Per Share | -0.20 | -0.22 | -0.33 | -0.08 | 0.32 | -1.57 |
Gross Margin | 31.09% | 35.31% | 29.37% | 29.40% | 1.65% | -8.60% |
Operating Margin | -42.29% | -35.68% | -44.96% | -28.88% | -71.16% | -147.47% |
Profit Margin | 215.70% | 156.62% | -69.33% | -11.82% | -61.55% | 29.05% |
Free Cash Flow Margin | -15.98% | -15.93% | -24.84% | -6.19% | 32.19% | -234.93% |
EBITDA | -16.14 | -13.92 | -17.21 | -6.97 | -21.68 | -25.94 |
EBITDA Margin | -29.44% | -22.66% | -29.79% | -12.48% | -50.51% | -90.15% |
D&A For EBITDA | 7.04 | 7.99 | 8.76 | 9.16 | 8.86 | 16.49 |
EBIT | -23.18 | -21.91 | -25.97 | -16.13 | -30.54 | -42.43 |
EBIT Margin | -42.29% | -35.68% | -44.96% | -28.88% | -71.16% | -147.47% |